COMP <GO>
CDRE vs ENOV // RSI-14 & 200D SMA MOMENTUM
Cadre Holdings Inc. (NYSE) VS. Enovis Corporation (NYSE) • 15-METRIC TALLY: CDRE 10
— ENOV 1
▲ RSI-14 & 200D SMA MOMENTUM LEADER: CDRE
LAST: $31.10 (+3.81%) • MKT CAP: $1.33B
rsi-technicals
65.0
LAST: $22.81 (+4.11%) • MKT CAP: $1.32B
rsi-technicals
48.3
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CDRE VS. ENOV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CDRE | ENOV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 42.50% | 59.80% | -17.30 | ENOV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.00% | -32.70% | +43.70 | CDRE | /roic <GO> |
| EV/EBITDA & P/E Valuation | 20.5x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 4.27% | 1.51% | +2.76 | CDRE | /fcf-yield <GO> |
| Operating Margin | 11.00% | -50.00% | +61.00 | CDRE | /operating-margins <GO> |
| Net Profit Margin | 7.20% | -52.70% | +59.90 | CDRE | /net-margins <GO> |
| Revenue Growth (YoY) | 7.50% | 6.70% | +0.80 | CDRE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.16% | 0.00% | +1.16 | CDRE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.32 | 0.20 | +3.12 | CDRE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | CDRE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 65.0 | 48.3 | +16.75 | CDRE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.1x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.33B | $1.32B | $16.3M | CDRE | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CDRE REV | ENOV REV | CDRE GROSS % | ENOV GROSS % | CDRE FCF | ENOV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $610.3M | $2.25B | 42.5% | 59.8% | $56.8M | $19.9M |
| FY 2024 | $567.6M | $2.11B | 41.1% | 56.0% | $26.1M | -$67.2M |
| FY 2023 | $482.5M | $1.71B | — | — | $73.2M | $135.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CDRE // BETA —
ENOV // BETA —